^
Association details:
| Biomarker: | MYCN amplification + ALK F1174V |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
Excerpt:
...brigatinib and crizotinib both inhibited cell growth of ALK addicted neuroblastoma lines...The IC50 values...crizotinib in CLB-BAR...186.40 ± 17.28 nM, respectively…
DOI:
10.18632/oncotarget.8508
